Khaire Niranjan S, Chhabra Prashant, Gupta Dikshat G, Jandial Aditya, Khadwal Alka, Kasudhan Kripa Shanker, Kaundal Shaweta, Chopra Madhu, Jain Arihant, Prakash Gaurav, Majhail Navneet S, Malhotra Pankaj, Lad Deepesh P
Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial, Nashville, USA.
Blood Cell Ther. 2022 Jun 10;5(3):83-86. doi: 10.31547/bct-2021-025. eCollection 2022 Aug 25.
There are existing international guidelines for long-term follow-up (LTFU) care of allogeneic hematopoietic cell transplantation (allo-HCT) survivors. However, implementing these guidelines represents a unique challenge in resource-challenged settings.
This study aimed to evaluate adherence to recommended surveillance in allo-HCT survivors at an academic center in North India and study the incidence of late effects. This single-center, retrospective study analyzed records of allo-HCT recipients from 2016 to 2020. Survivors were screened in our LTFU clinic at day +100 and +365 using cardiometabolic parameters (screening for hypertension, dyslipidemia, hyperglycemia, 24-hour urine protein, thyroid function), pulmonary function test (PFT), bone mineral density (BMD), and initiation of revaccination.
A total of 40/80 (50%) allo-HCT survivors were alive at a median of 888 days (IQR 515-1,306). The adherence to home-based screening parameters such as blood pressure and blood glucose was highest (>75%), followed by lab-based parameters (45-70%), and lowest for specialized tests such as PFT (<50%) at both day +100 and +365 time points. Adherence to the initiation of revaccination was only 67%. At least one cardiometabolic parameter was out of range in 55% and 63% of survivors at day +100 and +365, respectively.
The adherence to recommended surveillance measures for allo-HCT survivors in an academic LTFU clinic at one year was only 75% overall. Cardiometabolic abnormalities were noted in more than half of the survivors. This study emphasizes the need for a structured LTFU clinic in all centers performing HCT.
对于异基因造血细胞移植(allo-HCT)幸存者的长期随访(LTFU)护理,已有国际指南。然而,在资源匮乏的环境中实施这些指南面临独特挑战。
本研究旨在评估印度北部一家学术中心对allo-HCT幸存者推荐监测的依从性,并研究晚期效应的发生率。这项单中心回顾性研究分析了2016年至2020年allo-HCT受者的记录。在我们的LTFU诊所,于+100天和+365天使用心脏代谢参数(筛查高血压、血脂异常、高血糖、24小时尿蛋白、甲状腺功能)、肺功能测试(PFT)、骨密度(BMD)以及重新接种疫苗的起始情况对幸存者进行筛查。
共有40/80(50%)的allo-HCT幸存者存活,中位生存期为888天(四分位间距515 - 1306天)。在+100天和+365天这两个时间点,对基于家庭的筛查参数(如血压和血糖)的依从性最高(>75%),其次是基于实验室的参数(45 - 70%),而对于诸如PFT等专门测试的依从性最低(<50%)。重新接种疫苗起始的依从性仅为67%。在+100天和+365天,分别有55%和63%的幸存者至少有一项心脏代谢参数超出范围。
在一家学术性LTFU诊所,allo-HCT幸存者对推荐监测措施的一年总体依从性仅为75%。超过一半的幸存者存在心脏代谢异常。本研究强调在所有进行HCT的中心都需要一个结构化的LTFU诊所。